Why Johnson & Johnson Remains a Top Long-Term Investment in 2024
Johnson & Johnson remains a strong long-term investment due to its diverse product range and steady financial performance. The company has maintained its reputation as a reliable choice for investors, particularly after recent changes to its business structure.
In October 2023, J&J separated its consumer health division into a standalone company called Kenvue. This move allowed the firm to concentrate on its pharmaceutical and medical technology sectors. Despite the spin-off, none of its remaining products have yet reached $1 billion in annual sales since the split.
The loss of exclusivity for Stelara, once J&J's top-selling drug, initially posed a challenge. However, the company has since managed to offset this decline by strengthening other areas of its business. Executives recently stated they could now move past the impact of Stelara's patent expiration. With 28 products each generating over $1 billion annually, J&J continues to demonstrate financial resilience. Its strong free cash flow supports ongoing dividend increases, reinforcing its status as a Dividend King—having raised payouts for over 50 consecutive years. Currently, the company offers a $5.20 dividend, yielding 2.1%, which is nearly double the S&P 500's average of 1.1%. Pharmaceutical stocks like J&J often perform well during uncertain economic times. Their stable growth and lower risk exposure make them a preferred option for cautious investors.
J&J's ability to adapt and maintain financial strength keeps it among the top long-term stock picks. The company's focus on innovation, combined with its consistent dividend growth, provides a solid foundation for future stability. Investors continue to view it as a dependable choice in the healthcare sector.
